The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma
NCT ID: NCT01820884
Last Updated: 2024-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
240 participants
INTERVENTIONAL
2012-11-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Systematic Pelvic Lymphadenectomy Versus no Lymphadenectomy in Clinical Stage I-II Endometrial Cancer
NCT00482300
Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia
NCT04362046
Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With and Without Uterine Manipulator
NCT06307886
Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
NCT00002706
Risk-Reducing Surgeries for Hereditary Ovarian Cancer
NCT03294343
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Total Hysterectomy (TH)
Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
TH
Total hysterectomy
BPLND
bilateral pelvic and para-aortic lymph node dissection
TH and bilateral salpingo-oophorectomy (TH/BSO)
Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
TH/BSO
Total hysterectomy and bilateral salpingo-oophorectomy
BPLND
bilateral pelvic and para-aortic lymph node dissection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TH
Total hysterectomy
TH/BSO
Total hysterectomy and bilateral salpingo-oophorectomy
BPLND
bilateral pelvic and para-aortic lymph node dissection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female, Chinese women;
* premenopausal women；
* ≤ 50 years old;
* Pathological diagnosis by curettage/hysteroscopy : G1
* No prior treatment;
* Provide written informed consent.
Exclusion Criteria
* Family history of ovarian cancer;
* Suffering from other malignancies;
* Concurrently participating in other clinical trials;
* Unable or unwilling to sign informed consents;
* Unable or unwilling to abide by protocol.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Huazhong University of Science and Technology
OTHER
Zhejiang University
OTHER
Ding Ma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ding Ma
Director of the department of Obstetrics and Gynecology, Tongji Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beihua Kong, MD, PhD
Role: STUDY_CHAIR
Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Qilu Hospital，Shandong University
Jinan, Shandong, China
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-GYN/EC-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.